83 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 34751786 | Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. | 2022 May 4 | 1 |
2 | 34871844 | Synthesis and biological evaluation of novel PET tracers [18F]AG120 & [18F]AG135 for imaging mutant isocitrate dehydrogenase 1 expression. | 2022 Jan 1 | 3 |
3 | 35154988 | Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review. | 2022 Jan | 3 |
4 | 35190971 | Systemic Therapy for Chondrosarcoma. | 2022 Feb | 3 |
5 | 35198955 | The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma. | 2022 | 4 |
6 | 35259259 | FDA Approval Summary: Ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation. | 2022 Mar 8 | 3 |
7 | 35296436 | Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions. | 2022 Mar 13 | 3 |
8 | 35418865 | Ag120-Mediated Inhibition of ASCT2-Dependent Glutamine Transport has an Anti-Tumor Effect on Colorectal Cancer Cells. | 2022 | 4 |
9 | 35443108 | Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. | 2022 Apr 21 | 3 |
10 | 35460975 | IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia. | 2022 | 2 |
11 | 35532213 | Ivosidenib Boosts Azacitidine's Effectiveness in AML. | 2022 May 9 | 1 |
12 | 33024987 | Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. | 2021 Apr 1 | 1 |
13 | 33119479 | Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. | 2021 Jan 1 | 4 |
14 | 33397455 | Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML. | 2021 Jan 4 | 1 |
15 | 33493146 | Biliary cancer: gateway to comprehensive molecular profiling. | 2021 Jan | 1 |
16 | 33493392 | Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies. | 2021 May | 1 |
17 | 33683991 | Ivosidenib: an investigational drug for the treatment of biliary tract cancers. | 2021 Apr | 1 |
18 | 33709779 | Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma. | 2021 Jun | 3 |
19 | 33772143 | Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. | 2021 Nov | 1 |
20 | 33799004 | IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? | 2021 | 1 |
21 | 33822485 | PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. | 2021 Jun | 3 |
22 | 33832922 | Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling. | 2021 Apr | 4 |
23 | 33836133 | Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma. | 2021 May | 8 |
24 | 33898313 | IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. | 2021 | 1 |
25 | 33932504 | Practical considerations in screening for genetic alterations in cholangiocarcinoma. | 2021 Sep | 1 |
26 | 34071627 | Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia. | 2021 May 28 | 1 |
27 | 34188585 | Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence. | 2021 | 1 |
28 | 34313176 | Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome. | 2021 Dec | 2 |
29 | 34321251 | Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies. | 2021 Oct | 3 |
30 | 34554208 | Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. | 2021 Nov 1 | 6 |
31 | 34626563 | Current and emerging therapies for advanced biliary tract cancers. | 2021 Nov | 1 |
32 | 34889359 | What to use to treat AML: the role of emerging therapies. | 2021 Dec 10 | 1 |
33 | 31028664 | Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. | 2020 Apr | 5 |
34 | 31841594 | Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. | 2020 Feb 13 | 5 |
35 | 31910380 | Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia. | 2020 Jan | 3 |
36 | 32055803 | Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia. | 2020 Jan | 2 |
37 | 32171892 | Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. | 2020 Jul | 1 |
38 | 32208957 | Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. | 2020 May 20 | 3 |
39 | 32296873 | Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. | 2020 May | 5 |
40 | 32306411 | Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia. | 2020 Oct | 1 |
41 | 32380538 | Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. | 2020 May 12 | 2 |
42 | 32393603 | Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis. | 2020 Aug 15 | 3 |
43 | 32416072 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. | 2020 Jun | 5 |
44 | 32530764 | Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. | 2020 Oct 10 | 2 |
45 | 32588467 | Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation. | 2020 Nov | 5 |
46 | 32601974 | Treatment of Relapsed Acute Myeloid Leukemia. | 2020 Jun 29 | 3 |
47 | 32716208 | Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study. | 2020 Sep 1 | 6 |
48 | 32758465 | Ivosidenib for advanced IDH1-mutant cholangiocarcinoma. | 2020 Aug | 1 |
49 | 32758466 | Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors' reply. | 2020 Aug | 1 |
50 | 32808831 | Evaluating ivosidenib for the treatment of acute myeloid leukemia. | 2020 Dec | 3 |